SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Malloy who wrote (693)4/7/1999 12:57:00 PM
From: Bull-like  Read Replies (1) of 942
 
Brian-

There are 15 million type 2 diabetes patients in this country alone. In the past year when Rezulin was on the market, it had 750,000 users. The potential is huge, and far from being saturated. There are enough markets for all three drugs. The drugs from lly and smithKline are also PPAR gamma agonists, similar to troglitazone, so don't raise your hope about toxicity too high. As a lly share holder, I am just praying that their drug is as good as they claim to be. Bottome line? WLA will do well regardless, although they could be even bette without the two competitors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News